A Phase I Study of Extended Low Dose Temozolomide (SCH 52365, Temodar (R)) and Carmustine (BCNU) in the Treatment of Malignant Gliomas After Radiation Therapy

Trial Profile

A Phase I Study of Extended Low Dose Temozolomide (SCH 52365, Temodar (R)) and Carmustine (BCNU) in the Treatment of Malignant Gliomas After Radiation Therapy

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Apr 2013

At a glance

  • Drugs Carmustine (Primary) ; Temozolomide (Primary)
  • Indications Anaplastic astrocytoma; Glioblastoma; Glioma; Gliosarcoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Apr 2013 Actual end date Dec 2009 added as reported by ClinicalTrials.gov.
    • 03 Apr 2013 Last checked against ClinicalTrials.gov record.
    • 17 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top